Alkermes (ALKS) Total Non-Current Liabilities (2011 - 2026)
Alkermes (ALKS) reported Total Non-Current Liabilities of $2.4 billion for Q1 2026, up 376.7% year-over-year from $511.5 million in Q1 2025, and up 301.93% quarter-over-quarter from $606.7 million in Q4 2025.
Alkermes (ALKS) Total Non-Current Liabilities (2011 - 2026) Analysis & Trends
Alkermes (ALKS) has 16 years of Total Non-Current Liabilities data on file, last reported at $2.4 billion in Q1 2026.
- Total Non-Current Liabilities for Q1 2026 came in at $2.4 billion, up 376.7% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.4 billion (up 376.7% YoY), and the FY2025 annual result was $606.7 million, up 13.49% from the prior year.
- Total Non-Current Liabilities advanced to $2.4 billion in Q1 2026 per ALKS's latest filing, from $606.7 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $2.4 billion in Q1 2026 and troughed at $511.5 million in Q1 2025.
- A 5-year average of $859.5 million and a median of $856.2 million in 2022 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2024 and 2026: Total Non-Current Liabilities tumbled 39.5% in 2024, then soared 376.7% in 2026.
- A 5-year view of Total Non-Current Liabilities shows it stood at $877.8 million in 2022, then climbed by 0.66% to $883.7 million in 2023, then plunged by 39.5% to $534.6 million in 2024, then increased by 13.49% to $606.7 million in 2025, then jumped by 301.93% to $2.4 billion in 2026.
- Business Quant data shows ALKS's Total Non-Current Liabilities at $2.4 billion in Q1 2026, $606.7 million in Q4 2025, and $539.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 18.28 Bn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 11.64 Bn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 599.10 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | 44.12 Mn |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 1.24 Bn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 6.26 Bn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | 2.44 Bn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 1.13 Bn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | 1.81 Bn |
| 10 | Liquidia | 5.63 Bn | 5.40 Bn | 121.79 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.44 Bn |
| Dec 31, 2025 | 606.69 Mn |
| Sep 30, 2025 | 539.33 Mn |
| Jun 30, 2025 | 572.18 Mn |
| Mar 31, 2025 | 511.54 Mn |
| Dec 31, 2024 | 534.57 Mn |
| Sep 30, 2024 | 810.56 Mn |
| Jun 30, 2024 | 874.54 Mn |
| Mar 31, 2024 | 820.17 Mn |
| Dec 31, 2023 | 883.66 Mn |
| Sep 30, 2023 | 870.03 Mn |
| Jun 30, 2023 | 858.53 Mn |
| Mar 31, 2023 | 868.66 Mn |
| Dec 31, 2022 | 877.84 Mn |
| Sep 30, 2022 | 856.19 Mn |
| Jun 30, 2022 | 829.89 Mn |
| Mar 31, 2022 | 858.55 Mn |
| Dec 31, 2021 | 868.25 Mn |
| Sep 30, 2021 | 867.15 Mn |
| Jun 30, 2021 | 803.34 Mn |